Inspira Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
MWN-AI** Summary
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) announced on February 25, 2026, that it received a notice from Nasdaq indicating non-compliance with its Listing Rule 5550(b)(2). This rule mandates that companies on the Nasdaq Capital Market maintain a minimum market value of publicly held shares of $35 million. The written notice was received on February 19, 2026, and specifies that while the company is currently not in compliance, there are no immediate effects on its shares, which continue to trade under the symbol “IINN.”
In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Inspira has until August 18, 2026, to rectify this deficiency. The company must achieve and sustain a minimum market value of publicly held shares at or above $35 million for at least 10 consecutive business days within this period. If compliant status is not regained by the deadline, Nasdaq could initiate delisting procedures, although Inspira would have the opportunity to appeal any such decision to a hearings panel.
Inspira Technologies specializes in innovative medical devices, focusing on advanced respiratory support and real-time blood monitoring solutions. Its flagship product, the INSPIRA™ ART100 system, has received FDA clearance for cardiopulmonary bypass procedures in the U.S. The company is also developing the next-generation INSPIRA ART500, aimed at delivering oxygenation while patients are awake.
The press release underscores management's commitment to monitoring its market value and exploring options to restore compliance with Nasdaq requirements, but it also carries cautionary language regarding the uncertainties of achieving this goal. For more information, visit Inspira Technologies' official website.
MWN-AI** Analysis
Inspira Technologies (NASDAQ: IINN) has received a notification from Nasdaq regarding its failure to meet the minimum market value of publicly held shares requirement of $35 million. This notification, issued on February 19, 2026, allows Inspira 180 days to regain compliance or face potential delisting. While the company continues to trade under its symbol, investors should approach this stock with caution.
Inspira Technologies operates in the growing MedTech sector, focusing on innovative life-support and monitoring devices that have significant potential in the healthcare market. Given its FDA-cleared INSPIRA ART100 system and ongoing development of next-generation technologies, there's a fundamental strength to the company that could drive future growth. However, the immediate concern is its market capitalization, which is critical for maintaining its Nasdaq listing.
Investors should closely monitor the stock’s performance over the compliance period. Inspira needs to maintain its market value above $35 million for 10 consecutive business days to avoid delisting. If the company can achieve this, it might stabilize investor confidence and potentially lead to a rebound in stock price.
Furthermore, the management's intention to explore options for regaining compliance is a positive indicator of proactive leadership. However, it is essential to recognize the inherent risks; the company has not guaranteed its ability to meet compliance requirements, nor can it assure sustained viability under current market conditions.
For current investors, maintaining a watchful eye on market trends, trading volumes, and financial health, along with any corporate developments, is paramount. New investors may want to wait until there is clearer evidence of a recovery in market value or a strategic plan that explicitly outlines how Inspira plans to enhance its market presence and regain compliance. Given the uncertainties, prudent investing strategies, including diversification and risk management, are advisable for engagement with Inspira Technologies at this juncture.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Ra’anana, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that on February 19, 2026, it received written notice (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) advising the Company that it was not in compliance with Listing Rule 5550(b)(2) requiring companies listed on the Nasdaq Capital Market to maintain a minimum market value of publicly held shares of $35,000,000 (the “MVPHS Requirement”). Listing Rule 5550(b)(2) requires companies listed on the Nasdaq Capital Market to maintain a minimum market value of publicly held shares of $35,000,000. The Notice has no effect at this time on the listing of the Company's ordinary shares, which continues to trade on The Nasdaq Capital Market under the symbol “IINN.”
In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has a period of 180 calendar days, or until August 18, 2026 (the “Compliance Date”), to regain compliance with the MVPHS Requirement. To regain compliance, the Company's minimum market value of publicly held shares must close at $35,000,000 or more for a minimum of 10 consecutive business days prior to the Compliance Date. In the event the Company does not regain compliance with the MVPHS Requirement prior to the Compliance Date, Nasdaq will notify the Company that its securities are subject to delisting, at which point the Company may appeal the delisting determination to a Nasdaq hearings panel.
The Company intends to actively monitor its minimum market value of listed securities and may, if appropriate, consider implementing available options to regain compliance with the MVPHS Requirement. There can be no assurance that the Company will be able to regain compliance with Nasdaq Listing Rule 5550(b)(2) or maintain compliance with any other listing requirements.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.
Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses its ability to regain compliance with the MVPHS Requirement, its intentions to actively monitor its minimum market value of listed securities and its plans to consider implementing available options to regain compliance with the MVPHS Requirement. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC's website at www.sec.gov.
Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485
FAQ**
What specific strategies does Inspira Technologies OXY B.H.N. Ltd. (IINN) plan to implement to regain compliance with Nasdaq's MVPHS Requirement before the August 18, 2026 deadline?
How does Inspira Technologies OXY B.H.N. Ltd. (IINN) plan to enhance its market value to ensure it maintains compliance with Nasdaq Listing Rule 5550(b)(2)?
Given the recent compliance notice, what factors does Inspira Technologies OXY B.H.N. Ltd. (IINN) believe could influence its ability to regain market value?
What impact could a potential delisting have on the operational and financial future of Inspira Technologies OXY B.H.N. Ltd. (IINN) as they attempt to meet Nasdaq requirements?
**MWN-AI FAQ is based on asking OpenAI questions about Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN).
NASDAQ: IINN
IINN Trading
-5.11% G/L:
$0.5929 Last:
54,634 Volume:
$0.59 Open:
